Flunisolide NDC 50742-317

NDC codes

FDA NDC Directory

Product NDC (as listed)50742-317Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50742-0317Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50742-317-25	50742031725	1 BOTTLE, PUMP in 1 CARTON (50742-317-25) / 25 mL in 1 BOTTLE, PUMPMarketed from Jun 23, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Flunisolide
Generic name (nonproprietary): flunisolide
Active ingredients: Flunisolide — .25 mg/mL
Dosage form: Solution
Route: Nasal
Labeler: Ingenus Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207802
Marketing start: Jun 23, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 50742-317_139fb92c-bb10-4ee9-8572-679ac540aa27SPL ID 139fb92c-bb10-4ee9-8572-679ac540aa27SPL set ID f39cae46-c68f-47ef-82f3-4fd3dd46c74cRxCUI 1797863UNII QK4DYS664X
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450742031725 followed by a unit qualifier and the quantity

Package 50742-0317-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 30, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Flunisolide nasal solution should not be used in the presence of untreated localized infection involving nasal mucosa.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)